N-3 polyunsaturated fatty acids do not influence the efficacy of dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention

Cardiology Journal

Volumn 20, Issue 5, 2013, Pages 478-485

  Mizia Stec, Katarzyna ^a   Mizia, Magdalena ^a   Haberka, Maciej ^a   Lasota, Bartosz ^a   Gieszczyk Strózik, Klaudia ^a   Chmiel, Artur ^a   Najda, Jacek ^a   Gasior, Zbigniew ^a   Kyrcz Krzemień, Sławomira ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Aggregometry; Antiplatelet therapy; N 3 polyunsaturated fatty acids; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; OMEGA 3 ACID ETHYL ESTER; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6;

ADULT; AGED; ARTICLE; BARE METAL STENT; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; ECHOCARDIOGRAPHY; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; STABLE ANGINA PECTORIS; STENT THROMBOSIS; SUPPLEMENTATION; THROMBOCYTE AGGREGATION; TREATMENT DURATION; WHOLE BLOOD AGGREGOMETRY;

AGED; ANGINA, STABLE; ASPIRIN; BLOOD PLATELETS; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLAND; PROSPECTIVE STUDIES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885220540     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.2013.0132     Document Type: Article

References (30)

1. Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J, 2006; 27: 1341-1381.
2. Van der Werf, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the Management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J, 2008; 29: 2909-2945.
3. The ORIGIN Trial Investigators. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med, 2012; 367: 309-318.
4. von Schacky C, Weber PC. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest, 1985; 76: 2446-2450.
5. Thorngren M, Gustafson A. Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, platelet aggregation. Lancet, 1981; 2: 1190-1193.
6. Nordoy A, Bonaa KH, Sandset PW Hansen JB, Nilsen H. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipidemia in patients with combined hy-perlipidemia. Arteriosler Thromb Vase Biol, 2000; 20: 259-265.
7. Vanschoonbeek K, Wouters K, van der Meijden PE et al. Anticoagulant effect of dietary fish oil in hiperlipidemia: A study of hepatic gene expression in APOE2 knock-in mice. Arterioscler Thromb Vase Biol, 2008; 28: 2023-2029.
8. Barcelli U, Glas-Green wait P, Pollak VE. Enhancing effect on dietary supplementation with omega-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res, 2006; 118: 307-312.
9. Vanschoonbeek K, Feijge MA, Paquay M et al. Variable hypocoag-ulant effect of fish oil intake in humans: Modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vase Biol, 2004; 24: 1734-1740.
10. Eritsland J, Arnesen H, Seljeflot I, Kierilf R Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagul Fibrinolysis, 1995; 6:17-22.
11. Reís GJ, Boucher TM, Sipperly ME et al. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty Lancet, 1989; 2:177-181.
12. Mozaffarian D, Marchiolo R, Gardner T et al. The omega-3 fatty acids for prevention of post-operative atrial fibrillation (OPERA) trial-Rationale and design. Am Heart J, 2011; 162: 56-63.e3.
13. Balk E, Chung M, Lichtenstein A et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ). AHRQ Publication No. 04-E010-2. Rockville, MD: Agency for Healthcare Research and Quality 2004: 93: 1-6.
14. Wang C, Chung M, Lichtenstein A et al. Effects of omega-3 fatty acids on cardiovascular disease. Evid Rep Technol Assess (Summ), 2004; 93:1-8.
15. Kristenses SD, Iversen AM, Schmidt EB. n-3 polyunsaturated fatty acids and coronary thrombosis. Lipids, 2001; (26 suppl.): S79-S82.
16. Gajos G, Rostoff R Undas A, Piwowarska. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol, 2010; 55:1671-1678.
17. Gajos G, Zalewski J, Nessler J, Zmudka K, Undas A, Piwowarska W Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism. Kar-diol Pol, 2012; 70: 439-445.
18. Larson MK, Ashmore JH, Harris KA et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost, 2008; 100: 634-641.
19. Gremmel T, Calatzis A, Steiner S et al. Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel? Platelets, 2010; 21: 515-521.
20. Goodnight Jr, SH, Harris WS, Connor WE. The effects of dietary omega 3 fatty acids on platelet composition and function in man: A prospective, controlled study. Blood, 1981; 58: 880-885.
21. Larson MK, Shearer GC, Ashmore JH et al. Omega-3 fatty acids modulate collagen signaling in human platelets. Prostaglandins, Leucotrienes Fatty Acids, 2011; 84: 93-9.
22. Cohen MG, Rossi JS, Garbarino J et al. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: Beyond aspirin and clopidogrel. Thromb Res, 2011; 128: 335--340.
23. Guthikonda S, Alviar CL, Vaduganathan M et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol, 2008; 52: 743-749.
24. Cecchi E, Marcucci R, Paniccia R et al. Effect of blood he-matocrit and erythrocyte deformability on adenosine 5'-di-phosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy. Am J Cardiol, 2009; 104: 764-768.
25. Robier C, Neubauer M, Sternad H, Quehenberger F, Rainer, Neumeister R Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry Thromb Res, 2010; 126: 232-237.
26. van der Stelt CA, van Werkum JW, Seesing TH, Berg JM, Hackeng CM. To adjust or not to adjust the platelet count in light transmission aggregometry in patients receiving dual aspirin/clopidogrel treatment. Platelets, 2007; 18: 550-553.
27. Lordkipanidze M, Pharand C, Nguyen TA et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J, 2008; 29: 2877-2885.
28. Hobson AR, Qureshi Z, Banks R Curzen NR Effects of clopidogrel on aspirin specific pathways of platelet inhibition. Platelets, 2009; 20: 386-390.
29. Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost, 2010; 8: 613-615.
30. Gajos G, Zalewski J, Rostoff R Nessler J, Piwowarska W, Undas A. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on tpo of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI Clot). Arterioscler Thromb Vase Bid, 2011; 31: 1696-1702.